REGiMMUNE and Kiji Therapeutics Announce Intention to merge
The intended merger will create a pan-global Treg specialist to use multiple modalities to target Tregs for a number of indications. Taipei, TAIWAN, and Paris, FRANCE, October 18, 2024 – REGiMMUNE, the regulatory T cell targeting drugs for immunotherapy and Kiji Therapeutics, the specialist in Induced Pluripotent Stem Cells-Mesenchymal Stem Cells (IPSC-MSC) engineered cell therapies for [...]
REGiMMUNE Featured in “China Times”
TAIPEI, June 4, 2024 – REGiMMUNE Limited is pleased to announce that our company has recently been featured in a report by “China Times”. The article highlights our development progress of RGI-2001 and our future IPO plans. We are grateful for the attention and support from “China Times”. You can read the full article here: [...]
REGiMMUNE Welcomes Steve Yang as Chief Operating Officer
TAIPEI, May 6, 2024 – REGiMMUNE Limited, a clinical-stage biopharmaceutical company focused on creating innovative immunotherapies for immune disorders and cancer, is pleased to announce the appointment of Dr. Steve Yang as its Chief Operating Officer (COO), effective on May 6th 2024. In this role, Dr. Yang will lead the company’s operational strategies, driving product [...]
REGiMMUNE Announces the Poster Presentation at the AACR 2024 Annual Meeting for RGI-2001 Phase 2b latest analyses.
TAIPEI, April 11, 2024 – REGiMMUNE Limited, a clinical-stage biopharmaceutical company focused on creating innovative immunotherapies for immune disorders and cancer, today announces the poster presentation at the American Association of Cancer Research (AACR) Annual Meeting. The poster presentation is to highlight RGI-2001 phase 2b result, including the latest correlative analyses of changes in regulatory [...]
Tandem 2024: REGiMMUNE’s RGI-2001 Demonstrates Higher acute GFS without Increased Relapse from the Phase 2b Study
TAIPEI, February 22, 2024 – REGiMMUNE Limited, a clinical-stage biopharmaceutical company focused on creating innovative immunotherapies for immune disorders and cancer, today announced the positive results of their phase 2b clinical trial for the prevention of acute graft-versus-host disease (aGVHD) after allogeneic hematopoietic cell transplantation (alloHCT) at the 2024 Tandem Meeting of ASTCT and CIBMTR. [...]
REGiMMUNE to Present Results from the Phase 2b Study of RGI-2001 at the 2024 Tandem Meeting
TAIPEI, December 28, 2023 – REGiMMUNE Limited, a clinical-stage biopharmaceutical company focused on creating innovative immunotherapies for immune disorders and cancer, today announced that the Phase 2b clinical data from 48 patients receiving RGI-2001 for the prevention of acute graft-versus-host disease (aGVHD) will be presented at the 2024 Tandem Meeting in San Antonio, Texas on [...]
REGiMMUNE Signed Underwriting Contract with HuaNan Securities
Taipei, July 6, 2023 – REGiMMUNE Limited (REGiMMUNE), a biotech company focused on creating innovative immunotherapies for immune disorders and cancer, today appointed Hua Nan Securities as the lead underwriter for its upcoming initial public offering (IPO) in Taiwan. The IPO is anticipated to take place in 2025, signifying an important milestone in REGiMMUNE's expansion [...]
REGiMMUNE Licenses The Rights to Develop and Commercialize RGI-2001 To San Fu Biotech in Major Asian Countries
Taipei, March 29, 2023 – REGiMMUNE Limited (REGiMMUNE), a biotech company focused on creating innovative immunotherapies for immune disorders and cancer, and San Fu Biotech (SFB), a subsidiary of San Fu Chemical Co., Ltd. (4755.TW) have entered a licensing agreement to develop and commercialize RGI-2001 for the prophylaxis of acute Graft-versus-host disease (aGvHD) in major [...]
REGiMMUNE Presented Positive Results of RGI-2001 in the Reduction of Acute GvHD from Phase 2b Study at the 2022 ASH annual meeting
RGI-2001 was well tolerated and associated with a meaningful reduction in the incidence of severe acute GVHD TAIPEI, December 12, 2022 – REGiMMUNE Limited, a clinical-stage biopharmaceutical company developing innovative immunotherapies for immune disorders and cancer, today announced the positive results of their Phase 2b clinical trial for the prevention of acute graft-versus-host disease (aGvHD) [...]
REGiMMUNE to Present Results from the Phase 2b Study of RGI-2001 at the 2022 ASH Annual Meeting
TAIPEI, November 3, 2022 – REGiMMUNE Limited, a clinical-stage biopharmaceutical company focused on creating innovative immunotherapies for immune disorders and cancer, today announced that the Phase 2b clinical data from 49 patients receiving RGI-2001 for the prevention of acute graft-versus-host disease (aGVHD) will be presented at the 2022 American Society of Hematology (ASH) Annual Meeting [...]
REGiMMUNE Appoints Charlie Hsu as CFO
Taipei, 16 May 2022 – REGiMMUNE Limited, a biopharmaceutical company focused on creating innovative immunotherapies for rare diseases and cancer, today announced Charlie Hsu, a seasoned financial executive, join the company's management team as Chief Financial Officer (CFO). Charlie brings more than 25 years of business experience in finance management and equity investment in both [...]
REGiMMUNE presented at the ASH annual meeting on 5 December 2020
REGiMMUNE Corporation has presented clinical data on RGI-2001 Intravenous Infusion for the prevention of acute GVHD in the annual meeting of the American Society of Hematology on December 5 2020. Repeat weekly doses of RGI-2001 100 μg/kg IV infusion (30min) in allogeneic bone marrow transplant is safe when given with standard GvHD prophylaxis [...]
REGiMMUNE Completes $6 Million Series E Financing
Tokyo, Japan – April 7, 2017 – REGiMMUNE Corporation announced the closing of a Series E financing on April 7th. The company raised 6 million US in this new round, which was led by SMBC Venture Capital Co., Ltd., the VC arm of Sumitomo Mitsui Banking Corporation(SMBC) and Japan Asia Investment Corporation (JAIC). Additional investors [...]
Moving Headquarters Location
We are proud to announce that we have moved our business to a new location. Our new address is as follows. 35-3 Nihonbashi Hakozaki-cho BRICK GATE 5F Chuou-ku Tokyo 103-0015 Japan.Our Telephone numbers remain the same.
REGiMMUNE Appoints Kenzo Kosuda as Chief Executive Officer
Tokyo Japan — July 1, 2016 — REGiMMMUNE today announced that its Board of Directors has appointed Kenzo Kosuda as Chief Executive Officer effective July 1, 2016. Yasuyuki Ishii will assume the role of Executive Chairman on July 1, 2016, and will continue to serve as the Chairman of REGiMMUNE’s Board. "This is an appropriate [...]